speedy/RINGO cell cycle regulator family member E19, pseudogeneGenealiases: []
Q-omics provides the consensus-scored SPDYE19P profile across patient tissues and cancer cell-line models. SPDYE19P expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SPDYE19P is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, SPDYE19P RNA expression shows 16,836 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SKCM, HNSC, and KIRP as cancer lineages where SPDYE19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPDYE19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPDYE19P survival associations across molecular data types. SPDYE19P RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPDYE19P RNA expression–survival associations across cancer types. High SPDYE19P expression shows unfavorable associations in OV, COAD, LUSC and UVM, but favorable associations in SKCM and READ. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SPDYE19P RNA expression.
This table summarizes SPDYE19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPDYE19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPDYE19P shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, COAD, CHOL and KIRC. The HNSC box plot shows higher SPDYE19P RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .004).
This table shows molecular features associated with SPDYE19P in patient tissues and cancer cell lines. In patient samples, SPDYE19P shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
